On January 3rd, Jinshi Data reported that today, stem cell concept stocks opened with fluctuations. In terms of news, on January 2nd, the National Medical Products Administration conditionally approved the listing of the first stem cell therapy drug in China, Aimi Maitosai Injection, through a priority review and approval process, for the treatment of acute graft-versus-host disease (aGVHD) primarily affecting the gastrointestinal tract in patients over 14 years old who have failed hormone therapy. In this regard, reporters contacted Zhongyuan Union, Guanhao Biotech, and Landfar Bio-medicine regarding their stem cell business. Staff from Guanhao Biotech and Landfar Bio-medicine stated that the company mainly involves stem cell storage and currently does not have stem cell therapy drugs
